In terms of therapeutics, MRPS12 has been associated with tamoxifen resistance in breast cancer [24], where combination therapies including tigecycline inhibited proliferation and enabled selective toxicity in cancer cells [33, 34]. The gene discussed is MRPS12; the disease is breast cancer.